IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN MULTIPLE RECALL/REFRACTORY MYELOMA (MMRR): ANALYSIS OF HIGH-RISK PATIENT SUBGROUPS (PTS) FROM THE KARMMA STUDY

被引：0

作者：

Jesus, San-Miguel ^{[1
]}

Noopur, Raje S. ^{[2
]}

David, Siegel ^{[3
]}

Sundar, Jagannath ^{[4
]}

Sagar, Lonial ^{[5
]}

Nikhil, Munshi C. ^{[6
,7
]}

Philippe, Moreau ^{[8
]}

Hartmut, Goldschmidt ^{[9
,10
]}

Michele, Cavo ^{[11
]}

Anna, Truppel-Hartmann ^{[12
]}

Everton, Rowe ^{[13
]}

Huang Liping ^{[13
]}

Amit, Agarwal ^{[13
]}

Julie, Wang ^{[13
]}

Timothy, Campbell B. ^{[13
]}

Donna, Reece E. ^{[14
]}

机构：

[1] Clin Univ Navarra, Pamplona, Spain

[2] Hosp Gen Massachusetts, Boston, MA 02114 USA

[3] Ctr Med Univ Hackensack, Hackensack, NJ USA

[4] Mt Sinai Hosp, New York, NY 10029 USA

[5] Escuela Med Emory, Atlanta, GA USA

[6] Harvard Med Sch, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA

[7] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

[8] Ctr Hosp Univ Nantes, Nantes, France

[9] Hosp Univ Heidelberg, Heidelberg, Germany

[10] Natl Ctr Tumor Dis, Heidelberg, Germany

[11] Bologna Univ, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[12] Bluebird Bio, Cambridge, MA USA

[13] Bristol Myers Squibb, Princeton, NJ USA

[14] Ctr Oncol Princess Margaret, Toronto, ON, Canada

来源：

HAEMATOLOGICA | 2021年 / 106卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

CO-069

引用

页码：77 / 77

页数：1

共 50 条

[31] Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
Delforge, Michel
Otero, Paula Rodriguez
Shah, Nina
Moshkovich, Olga
Braverman, Julia
Dhanda, Devender S.
Lanar, Sally
Devlen, Jennifer
Miera, Matthew
Gerould, Heather
Campbell, Timothy B.
Munshi, Nikhil C.
LEUKEMIA RESEARCH, 2023, 129
[32] Estimation of post-infusion costs of care for patients in the US with relapsed and refractory multiple myeloma (RRMM) who received idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa clinical trial
McGarvey, November
Ung, Brian
Carattini, Thomas
Campbell, Timothy
Lee, Abraham
Patwardhan, Pallavi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S181 - S181
[33] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
Anderson, Larry D., Jr.
Shah, Nina
Jagannath, Sundar
Berdeja, Jesus G.
Lonial, Sagar
Raje, Noopur
Siegel, David S.
Lin, Yi
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Einsele, Hermann
Goldschmidt, Hartmut
Weisel, Katja
Cavo, Michele
Reece, Donna E.
Rambaldi, Alessandro
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S17 - S18
[34] KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma
Delforge, Michel
Baz, Rachid C.
Cavo, Michele
Callander, Natalie S.
Ghobadi, Armin
Rodriguez-Otero, Paula
Mateos, Maria-Victoria
Massaro, Monica
Ding, Li
Patel, Payal
Pittari, Gianfranco
Novick, Steven
Giralt, Sergio A.
Berdeja, Jesus G.
BLOOD, 2020, 136
[35] Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
Munshi, Nikhil C.
Anderson, Larry D., Jr.
Shah, Nina
Jagannath, Sundar
Berdeja, Jesus G.
Lonial, Sagar
Raje, Noopur S.
Siegel, David Samuel DiCapua
Lin, Yi
Oriol, Albert
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Petrocca, Fabio
Connarn, Jamie
Patel, Payal
Huang, Liping
Campbell, Timothy Brandon
Hege, Kristen
San Miguel, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[36] HEALTHCARE RESOURCE UTILIZATION AND 2022 COST UPDATE OF CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM) RECEIVING IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN KARMMA
McGarvey, N.
Imanak, K.
Carattini, T.
Ung, B.
Campbell, T. B.
Gitlin, M.
Patwardhan, P.
VALUE IN HEALTH, 2023, 26 (06) : S89 - S89
[37] Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial
Shah, Nina
Munshi, Nikhil C.
Berdeja, Jesus G.
Jagannath, Sundar
Finney, Olivia
Martin, Nathan
Agarwal, Amit
Rowe, Everton
Campbe, Timothy B.
San-Miguel, Jesus F.
BLOOD, 2021, 138
[38] Idecabtagene vicleucel (ide-cel) vs standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 analysis in high-risk subgroups
Raab, Marc S.
Patel, Krina
Rodriguez-Otero, Paula
Manier, Salomon
Baz, Rachid
Cavo, Michele
Callander, Natalie
Costa, Luciano J.
Moreau, Philippe
Solomon, Scott R.
Chen, Christine
Raje, Noopur
Scheid, Christoph
Delforge, Michel
Larsen, Jeremy
Pabst, Thomas
Suzuki, Kenshi
Truppel-Hartmann, Anna
Piasecki, Julia
Felten, Jasper
Caia, Andrea
Cook, Mark
Giralt, Sergio
Mateos, Maria-Victoria
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 144 - 144
[39] Healthcare resource utilization and economic burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving idecabtagene vicleucel (ide-cel, bb2121) in KarMMa.
Hari, Parameswaran
Nguyen, Andy
Pelletier, Corey
McGarvey, November
Gitlin, Matthew
Parikh, Kejal
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
[40] Tumor profiling of idecabtagene vicleucel (ide-cel, bb2121) patients in KarMMa showed comparable responses in existing molecular high-risk subsets and preliminary gene signature of durable response
Martin, Nathan
Xu, Amy
Stong, Nicholas
Rytlewski, Julie
Finney, Olivia
Campbell, Timothy
Pierceall, William
Flynt, Erin
Thompson, Ethan
Kaiser, Shari
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S44 - S45

← 1 2 3 4 5 →